Search company, investor...
X-Chem company logo


Founded Year



Acq - Fin | Alive

Total Raised


About X-Chem

X-Chem applies its drug discovery capabilities to the discovery of compounds against therapeutic targets. X-Chem's internal program is to screen targets in stem cell biology using the BIND Scanner instrument developed and marketed by SRU Biosystems, a label-free, microplate-based system for profiling compounds that affect stem cell growth, health, and differentiation.

Headquarters Location

100 Beaver Street Suite 101

Waltham, Massachusetts, 02453,

United States


Missing: X-Chem's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: X-Chem's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing X-Chem

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned X-Chem in 1 CB Insights research brief, most recently on Dec 12, 2022.

Expert Collections containing X-Chem

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

X-Chem is included in 3 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

1,568 items


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

X-Chem Patents

X-Chem has filed 10 patents.

The 3 most popular patent topics include:

  • Analgesics
  • Biotechnology
  • Cell biology
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, DNA, Biotechnology, Nucleotides, Drug discovery


Application Date


Grant Date



Related Topics

Molecular biology, DNA, Biotechnology, Nucleotides, Drug discovery



Latest X-Chem News

X-Chem and Kymera Expand Existing Partnership

Jan 31, 2023

January 31, 2023 08:00 AM Eastern Standard Time WALTHAM, Mass.--( BUSINESS WIRE )-- X-Chem , the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc. (NASDAQ: KYMR). With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera — with X-Chem applying its world-leading DEL platform to support Kymera’s discovery of first- and best-in-class protein degraders. The expanded partnership comprises 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration. “Having worked with multiple DEL providers, we have been impressed with the quality of X-Chem’s libraries and their scientific rigor,” said Nello Mainolfi, Ph.D., Founder, President and CEO of Kymera Therapeutics. “Kymera’s unique target selection strategy is critical to our success, and X-Chem has been a valued partner in helping us to unlock challenging disease targets that can be only or best addressed by targeted protein degradation. We look forward to extending our collaboration and working together to discover revolutionary new medicines.” Matt Clark, CEO of X-Chem, said, “The team at Kymera has built an amazing company that is a leader in the targeted protein degradation field. We are delighted to be able to work more closely with Kymera and help them discover more compounds that positively impact patients.” About X-Chem X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI. About Kymera Therapeutics Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most promising targets and provide patients with more effective treatments. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit . Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” company by Fierce Biotech and has been recognized by both the Boston Globe and the Boston Business Journal as one of Boston’s top workplaces. For more information about our people, science, and pipeline, please visit or follow us on Twitter or LinkedIn. Contacts

X-Chem Frequently Asked Questions (FAQ)

  • When was X-Chem founded?

    X-Chem was founded in 2010.

  • Where is X-Chem's headquarters?

    X-Chem's headquarters is located at 100 Beaver Street, Waltham.

  • What is X-Chem's latest funding round?

    X-Chem's latest funding round is Acq - Fin.

  • How much did X-Chem raise?

    X-Chem raised a total of $8.5M.

  • Who are the investors of X-Chem?

    Investors of X-Chem include GHO Capital Partners and PPD.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.